The Laryngoscope · 2026
Safety Profile in Hyaluronic Acid-Based Vocal Fold Injection Augmentation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thornton Noah, Stepp Ryan, Nguyenkhoa Vincent, Leder Macek Aleeza, Daniero James J
Аннотация
OBJECTIVE: The study's objective is to assess the safety profile and complication rates of hyaluronic acid-based vocal fold injection augmentation (VFIA), specifically evaluating inflammatory reactions, injection volume, and COVID-19 vaccination status.
METHODS: A retrospective cohort study was conducted of 299 VFIA procedures performed using Restylane-L at a single academic institution. Medical charts were reviewed to collect patient demographics, injection details (approach, location, and volume), videolaryngostroboscopy exams, and post-injection outcomes, including complication rates and nature of inflammatory reactions.
RESULTS: The overall complication rate was 4.0% (12/299), with inflammatory complications comprising 2.34% (7/299) of cases. Inflammatory symptoms developed a mean of 4.3 days after injection (median: 3 days; range: 12 h-10 days) and resolved in all cases with corticosteroid therapy. A statistically significant difference in injection volume was noted among groups (p = 0.037), although post hoc comparisons did not demonstrate significance. COVID-19 vaccination status was not associated with complication rates (p = 0.84).
CONCLUSIONS: VFIA using HA-based material demonstrates a low rate of complications, and all inflammatory reactions resolved with medical management. Injection volume may play a role in complication risk, but further multi-site studies are needed. No association between COVID-19 vaccination and adverse outcomes was identified.
METHODS: A retrospective cohort study was conducted of 299 VFIA procedures performed using Restylane-L at a single academic institution. Medical charts were reviewed to collect patient demographics, injection details (approach, location, and volume), videolaryngostroboscopy exams, and post-injection outcomes, including complication rates and nature of inflammatory reactions.
RESULTS: The overall complication rate was 4.0% (12/299), with inflammatory complications comprising 2.34% (7/299) of cases. Inflammatory symptoms developed a mean of 4.3 days after injection (median: 3 days; range: 12 h-10 days) and resolved in all cases with corticosteroid therapy. A statistically significant difference in injection volume was noted among groups (p = 0.037), although post hoc comparisons did not demonstrate significance. COVID-19 vaccination status was not associated with complication rates (p = 0.84).
CONCLUSIONS: VFIA using HA-based material demonstrates a low rate of complications, and all inflammatory reactions resolved with medical management. Injection volume may play a role in complication risk, but further multi-site studies are needed. No association between COVID-19 vaccination and adverse outcomes was identified.